Overview

Mass Balance and Metabolic Profiling of [14C]AZD5672 in Healthy Male Volunteers

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine how the body breaks down and excretes the investigational drug, AZD5672.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide